These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 25397550)

  • 1. Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study.
    Spagnuolo V; Galli L; Bigoloni A; Nozza S; Monforte Ad; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19806. PubMed ID: 25397550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
    Castagna A; Spagnuolo V; Galli L; Vinci C; Nozza S; Carini E; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Lazzarin A;
    AIDS; 2014 Sep; 28(15):2269-79. PubMed ID: 25058680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
    Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
    J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
    Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19808. PubMed ID: 25397552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.
    Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
    Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
    Colella E; Cattaneo D; Galli L; Baldelli S; Clementi E; Galli M; Lazzarin A; Castagna A; Rusconi S; Spagnuolo V
    New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Palacios R; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    J Antimicrob Chemother; 2017 Jan; 72(1):246-253. PubMed ID: 27629070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
    Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P
    AIDS; 2010 Sep; 24(15):2365-74. PubMed ID: 20802297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials.
    Arribas J; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19788. PubMed ID: 25397532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
    AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
    Clumeck N; Rieger A; Banhegyi D; Schmidt W; Hill A; Van Delft Y; Moecklinghoff C; Arribas J
    J Antimicrob Chemother; 2011 Aug; 66(8):1878-85. PubMed ID: 21652619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
    Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
    HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.
    Valantin MA; Lambert-Niclot S; Flandre P; Morand-Joubert L; Cabiè A; Meynard JL; Ponscarme D; Ajana F; Slama L; Curjol A; Cuzin L; Schneider L; Taburet AM; Marcelin AG; Katlama C;
    J Antimicrob Chemother; 2012 Mar; 67(3):691-5. PubMed ID: 22160145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.